Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$21.33 USD
-1.89 (-8.14%)
Updated May 29, 2024 04:00 PM ET
After-Market: $21.37 +0.04 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ELVN 21.33 -1.89(-8.14%)
Will ELVN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
3 Stocks in the Limelight on New Analyst Coverage
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELVN
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
Strong Buy Rating for Enliven Therapeutics’ ELVN-001 Amid Favorable Market Dynamics
Short Report: GameStop, AMC Entertainment bears retreat further
Enliven Therapeutics: A Strong Buy on Market Dynamics and Scemblix’s Breakthrough Therapy Designation Impact
Analysts Offer Insights on Healthcare Companies: Iridex (IRIX), Nyxoah (NYXH) and Enliven Therapeutics (ELVN)